Targeting adenosine for cancer immunotherapyRobert D. Leone, Leisha A. Emens
18 June 2018
Significance and implications of FDA approval of pembrolizumab for biomarker-defined diseaseMichael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley
14 May 2018
Immunotherapy for Merkel cell carcinoma: a turning point in patient careIsaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson
23 March 2018
Current clinical trials testing the combination of immunotherapy with radiotherapyJosephine Kang, Sandra Demaria, Silvia Formenti
20 September 2016
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyHasan Rehman, Ann W. Silk, Michael P. Kane, Howard L. Kaufman
20 September 2016
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Claud Grigg, Naiyer A. Rizvi
16 August 2016
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccineDavid B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox
17 May 2016